Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | CNR1 | P21554 | 2/20 | 0.50 |
| ▸ | CNR2 | P34972 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | DGKA | P23743 | 1/20 | 0.49 |
| ▸ | MGLL | Q99685 | 1/20 | 0.48 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17352278 | 0.96 | DGKA (0.52) | FAAHDGKA | |
| SCHEMBL354126 | 0.92 | ALDH1A1 (0.50) | FAAHALDH1A1HPGDDUSP3 | |
| SCHEMBL127955 | 0.87 | GPR84 (0.55) | MAPTDUSP3 | |
| SCHEMBL1123301 | 0.87 | GPR84 (0.55) | MAPTDUSP3 | |
| SCHEMBL1123651 | 0.87 | GPR84 (0.55) | MAPTDUSP3 | |
| SCHEMBL28765162 | 0.86 | MGLL (0.55) | FAAHALDH1A1CNR1CNR2MAPT | |
| SCHEMBL154132 | 0.85 | FAAH (0.62) | FAAHALDH1A1CNR1CNR2MAPT | |
| SCHEMBL17512200 | 0.84 | ALDH1A1 (0.51) | FAAHALDH1A1HPGDDUSP3 | |
| SCHEMBL27786702 | 0.84 | ALDH1A1 (0.51) | ALDH1A1HPGDDUSP3 | |
| SCHEMBL18662301 | 0.83 | ALDH1A1 (0.57) | FAAHALDH1A1CNR1CNR2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105120839-B | Injectable long-acting local anesthetic semisolid preparation and composition components thereof | 湖州惠中济世生物科技有限公司 | 2020-07-28 | — | — | CN | disclosed |
| EP-2961380-B1 | INJECTABLE LONG-ACTING LOCAL ANESTHETIC SEMI-SOLID FORMULATIONS AND ITS COMPOSITIONS | MIRA PHARMA CORP (US) | 2020-04-08 | — | — | EP | disclosed |
| US-10220093-B2 | Long-acting semi-solid lipid formulations | MIRA PHARMA CORPORATION (US) | 2019-03-05 | — | — | US | disclosed |
| US-20180104340-A1 | LONG-ACTING SEMI-SOLID LIPID FORMULATIONS | HUZHOU HUI ZHONG JI SHI BIOTECHNOLOGY CO., LTD (CN) | 2018-04-19 | — | — | US | disclosed |
| US-9849180-B2 | Long-acting semi-solid lipid formulations | SHEN HUI RONG (US) | 2017-12-26 | — | — | US | disclosed |
| US-20160074513-A1 | Long-Acting Semi-Solid Lipid Formulations | SHEN HUI RONG (US) | 2016-03-17 | — | — | US | disclosed |
| US-20150366967-A1 | Injectable Long-Acting Local Anesthetic Semi-Solid Formulations and Its Compositions | HUZHOU HUI ZHONG JI SHI BIOTECHNOLOGY CO., LTD (CN) | 2015-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160074513-A1 | Long-Acting Semi-Solid Lipid Formulations | LIPA, LPXN, LIPE | FAAH 177/4885ALDH1A1 4451/4885CNR1 1424/4885 |
| US-20180104340-A1 | LONG-ACTING SEMI-SOLID LIPID FORMULATIONS | LPXN, LIPA, CRH | FAAH 61/4885ALDH1A1 3888/4885CNR1 1393/4885 |
| US-20150366967-A1 | Injectable Long-Acting Local Anesthetic Semi-Solid Formulations and Its Compositions | LPXN, ALOX5, ADRA2A | FAAH 164/4885ALDH1A1 2701/4885CNR1 1239/4885 |
| US-10220093-B2 | Long-acting semi-solid lipid formulations | LPXN, LIPA, CRH | FAAH 61/4885ALDH1A1 3888/4885CNR1 1393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.